Drug Type Small molecule drug |
Synonyms AMX-3009, AMX3009马来酸 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | China | 21 Jun 2024 | |
Breast Carcinoma Metastatic in the Brain | Phase 1 | China | 30 Jan 2022 | |
Lung Cancer with Brain Metastasis | Phase 1 | China | 30 Jan 2022 | |
HER2 Positive Solid Tumors | Phase 1 | China | 02 Jul 2020 | |
Locally Advanced Malignant Solid Neoplasm | IND Approval | China | 22 Mar 2024 | |
Metastatic Solid Tumor | IND Approval | China | 22 Mar 2024 | |
Squamous Cell Carcinoma of Head and Neck | IND Approval | China | 22 Mar 2024 | |
Breast Cancer | IND Application | China | 22 Feb 2019 | |
Pancreatic Cancer | IND Application | China | 22 Feb 2019 | |
Stomach Cancer | IND Application | China | 22 Feb 2019 |